Merck (MRK) and Eisai (ESALF) announce that the EMA's Committee for Medicinal Products for Human Use ((CHMP)) has adopted positive opinions recommending approval of the...
Shares of Merck & Co. Inc. were down 0.1% in premarket trading on Friday, the day after the Food and Drug Administration said it plans to convene an advisory committee on Nov. 30...
Merck (MRK) announces that the EMA's Committee for Medicinal Products for Human Use ((CHMP)) has recommended the approval of VAXNEUVANCE (Pneumococcal 15-valent Conjugate...
Merck (MRK) is one of the largest international healthcare companies, focusing on delivering innovative health solutions through its prescription medicines, vaccines, biologic...
Merck To Double Production Of 'Breakthrough' COVID Drug As Nations Line Up To BuyDespite safety concerns raised by multiple scientists, Merck is signing deals with countries left...
I am neutral on Merck (MRK), because its valuation multiples indicate that it trades in line with fair value based on its past history.Merck is an American multinational,...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Buy |
| Summary | Strong Buy | Buy | Strong Sell | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 4.30 | 4.36 | 4.29 | -0.00 | 0.00% | 2.42M | Philippines | |||
| 3,220.00 | 3,350.00 | 3,212.00 | 0.00 | 0.00% | 98.27K | Philippines | |||
| 115.50 | 115.50 | 114.80 | 0.00 | 0.00% | 76.81K | Philippines | |||
| 9.10 | 9.25 | 9.03 | -0.000 | 0.00% | 24.39M | Philippines | |||
| 90.00 | 99.50 | 89.10 | 0.00 | 0.00% | 386.89K | Philippines | |||
| 133.20 | 134.40 | 133.00 | 0.00 | 0.00% | 1.43M | Philippines | |||
| 14.70 | 15.40 | 14.50 | 0.000 | 0.00% | 1.12M | Philippines | |||
| 7.28 | 7.42 | 7.27 | -0.0000 | 0.00% | 6.82M | Philippines | |||
| 3.33 | 3.48 | 3.31 | 0.00 | 0.00% | 9.67M | Philippines | |||
| 229.00 | 229.00 | 229.00 | 0.00 | 0.00% | 40.00 | Philippines | |||
| 3.11 | 3.15 | 3.09 | 0.000 | 0.00% | 19.86M | Philippines | |||
| 11.32 | 11.70 | 11.10 | 0.000 | 0.00% | 65.57M | Philippines | |||
| 15.34 | 15.72 | 15.32 | -0.000 | 0.00% | 1.71M | Philippines | |||
| 229.80 | 234.80 | 226.00 | -0.00 | 0.00% | 1.26M | Philippines | |||
| 0.31 | 0.00 | 0.00 | 0.0000 | 0.00% | 12.26M | Philippines |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations, as well as with IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of a specific version of Mallya device. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.